Pharmaceutical major Dr.Reddy’s Laboratories on Monday announced the launch of Nise D spray, emphasizing its strategic intent of being a player of substance in the Indian OTC (Over The Counter) space.
Nise D spray, the company said, offers quick and targeted pain killing. Through this product Dr.Reddy’s has further expanded its offerings in the therapeutic area of pain relief to consumers.
In India, according to A C Nielson Retail Management Study, the market for pain relief products is approximately Rs.1,700 crore. Pain relief sprays are growing 20 times faster than creams and gels, indicating a trend of changing consumer preferences.
The formulation for Nise D Spray is stated to be comprising three key ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation.
“Nise D Spray marks our entry into the new segment and further boosts our OTC portfolio. Nise gel has made a remarkable headway into the market and looking at the market dynamics and consumer requirements, we expect Nise D Spray to have a great momentum and significant market share across regions”, M.V. Ramana, Dr. Reddy's Executive Vice President and Head Branded Markets (India & Emerging countries), stated in a press release.
